Intralesional Therapy with Interleukin-2 for Melanoma
Author Information
Author(s): Radny P, Caroli U M, Bauer J, Paul T, Schlegel C, Eigentler T K, Weide B, Schwarz M, Garbe C
Primary Institution: Eberhard-Karls-University, Tübingen, Germany
Hypothesis
Is intralesional IL-2 effective in treating soft-tissue metastasis when other therapies have failed?
Conclusion
Intralesional IL-2 therapy shows a high response rate in treating soft-tissue melanoma metastases.
Supporting Evidence
- 15 patients achieved complete regression of all treated lesions.
- 85% of treated metastases showed complete regression.
- Patients tolerated the treatment well with limited side effects.
Takeaway
Doctors tested a new way to treat skin cancer by injecting a medicine called IL-2 directly into the tumors, and it worked really well for many patients.
Methodology
Patients received intralesional injections of IL-2, and their responses were assessed based on clinical evaluations and histopathology.
Limitations
The study was small and did not include survival as an endpoint.
Participant Demographics
14 females and 10 males, aged 19–83 years, with AJCC stage III–IV melanoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website